Waters Corporation (0LTI.L)
USD 370.56
(-0.36%)
USD 370.56
(-0.36%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.35 Billion USD | 42.65% |
| 2022 | 1.65 Billion USD | 9.08% |
| 2021 | 1.51 Billion USD | 11.6% |
| 2020 | 1.35 Billion USD | -19.31% |
| 2019 | 1.68 Billion USD | -26.8% |
| 2018 | 2.29 Billion USD | -41.04% |
| 2017 | 3.89 Billion USD | 10.37% |
| 2016 | 3.52 Billion USD | 11.64% |
| 2015 | 3.16 Billion USD | 115.76% |
| 2014 | 1.46 Billion USD | 10.72% |
| 2013 | 1.32 Billion USD | 12.36% |
| 2012 | 1.17 Billion USD | 18.87% |
| 2011 | 990.83 Million USD | 29.34% |
| 2010 | 766.05 Million USD | 21.25% |
| 2009 | 631.77 Million USD | 17.84% |
| 2008 | 536.12 Million USD | -39.37% |
| 2007 | 884.17 Million USD | -2.13% |
| 2006 | 903.46 Million USD | 9.34% |
| 2005 | 826.28 Million USD | 80.94% |
| 2004 | 456.66 Million USD | 85.4% |
| 2003 | 246.3 Million USD | 9142.36% |
| 2002 | 2.66 Million USD | 133.77% |
| 2001 | 1.14 Million USD | -76.63% |
| 2000 | 4.87 Million USD | -94.88% |
| 1999 | 95.3 Million USD | -57.19% |
| 1998 | 222.6 Million USD | -28.81% |
| 1997 | 312.7 Million USD | 47.36% |
| 1996 | 212.2 Million USD | 32.29% |
| 1995 | 160.4 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 25.34 Million USD | -8.8% |
| 2024 Q2 | 2.08 Billion USD | -2.33% |
| 2024 Q1 | 2.13 Billion USD | -12.44% |
| 2023 Q4 | 2.44 Billion USD | -5.78% |
| 2023 Q2 | 2.72 Billion USD | 73.78% |
| 2023 FY | 2.35 Billion USD | 42.65% |
| 2023 Q1 | 1.56 Billion USD | -5.11% |
| 2023 Q3 | 2.59 Billion USD | -4.81% |
| 2022 Q1 | 1.47 Billion USD | -4.64% |
| 2022 FY | 1.65 Billion USD | 9.08% |
| 2022 Q4 | 1.65 Billion USD | 2.0% |
| 2022 Q3 | 1.61 Billion USD | 3.8% |
| 2022 Q2 | 1.55 Billion USD | 6.08% |
| 2021 FY | 1.51 Billion USD | 11.6% |
| 2021 Q1 | 1.82 Billion USD | 19.27% |
| 2021 Q4 | 1.54 Billion USD | -6.02% |
| 2021 Q2 | 1.63 Billion USD | -10.88% |
| 2021 Q3 | 1.64 Billion USD | 0.58% |
| 2020 Q3 | 1.74 Billion USD | -6.67% |
| 2020 Q4 | 1.53 Billion USD | -12.23% |
| 2020 FY | 1.35 Billion USD | -19.31% |
| 2020 Q1 | 3.8 Billion USD | 14.32% |
| 2020 Q2 | 1.87 Billion USD | -50.78% |
| 2019 FY | 1.68 Billion USD | -26.8% |
| 2019 Q4 | 3.32 Billion USD | 24.55% |
| 2019 Q1 | 2.26 Billion USD | -1.39% |
| 2019 Q3 | 2.67 Billion USD | 18.06% |
| 2019 Q2 | 2.26 Billion USD | -0.04% |
| 2018 Q3 | 2.29 Billion USD | 0.0% |
| 2018 Q1 | 2.49 Billion USD | -35.93% |
| 2018 Q4 | 2.29 Billion USD | 0.01% |
| 2018 FY | 2.29 Billion USD | -41.04% |
| 2018 Q2 | 2.29 Billion USD | -7.98% |
| 2017 Q1 | 3.5 Billion USD | -0.56% |
| 2017 Q4 | 3.89 Billion USD | 5.56% |
| 2017 Q3 | 3.69 Billion USD | 2.51% |
| 2017 Q2 | 3.59 Billion USD | 2.57% |
| 2017 FY | 3.89 Billion USD | 10.37% |
| 2016 Q2 | 3.38 Billion USD | 2.31% |
| 2016 FY | 3.52 Billion USD | 11.64% |
| 2016 Q4 | 3.52 Billion USD | 2.63% |
| 2016 Q3 | 3.43 Billion USD | 1.48% |
| 2016 Q1 | 3.31 Billion USD | 4.77% |
| 2015 Q3 | 3.08 Billion USD | 4.75% |
| 2015 Q4 | 3.16 Billion USD | 2.47% |
| 2015 Q1 | 2.79 Billion USD | 90.77% |
| 2015 Q2 | 2.94 Billion USD | 5.37% |
| 2015 FY | 3.16 Billion USD | 115.76% |
| 2014 Q4 | 1.46 Billion USD | 2.46% |
| 2014 Q1 | 1.33 Billion USD | 0.66% |
| 2014 Q2 | 1.39 Billion USD | 4.6% |
| 2014 Q3 | 1.43 Billion USD | 2.63% |
| 2014 FY | 1.46 Billion USD | 10.72% |
| 2013 Q2 | 1.26 Billion USD | 2.81% |
| 2013 FY | 1.32 Billion USD | 12.36% |
| 2013 Q4 | 1.32 Billion USD | 2.29% |
| 2013 Q3 | 1.29 Billion USD | 2.04% |
| 2013 Q1 | 1.23 Billion USD | 4.71% |
| 2012 Q1 | 1.02 Billion USD | 3.31% |
| 2012 Q2 | 1.1 Billion USD | 7.59% |
| 2012 Q3 | 1.14 Billion USD | 4.21% |
| 2012 Q4 | 1.17 Billion USD | 2.62% |
| 2012 FY | 1.17 Billion USD | 18.87% |
| 2011 Q2 | 836.17 Million USD | 5.8% |
| 2011 FY | 990.83 Million USD | 29.34% |
| 2011 Q1 | 790.34 Million USD | 3.17% |
| 2011 Q3 | 971.57 Million USD | 16.19% |
| 2011 Q4 | 990.83 Million USD | 1.98% |
| 2010 Q1 | 712.38 Million USD | 12.76% |
| 2010 FY | 766.05 Million USD | 21.25% |
| 2010 Q4 | 766.05 Million USD | -3.31% |
| 2010 Q3 | 792.24 Million USD | 4.68% |
| 2010 Q2 | 756.85 Million USD | 6.24% |
| 2009 Q2 | 630.75 Million USD | 7.26% |
| 2009 FY | 631.77 Million USD | 17.84% |
| 2009 Q4 | 631.77 Million USD | -2.0% |
| 2009 Q3 | 644.65 Million USD | 2.2% |
| 2009 Q1 | 588.05 Million USD | 9.69% |
| 2008 Q2 | 984.02 Million USD | 5.89% |
| 2008 FY | 536.12 Million USD | -39.37% |
| 2008 Q4 | 536.12 Million USD | -47.82% |
| 2008 Q1 | 929.3 Million USD | 5.1% |
| 2008 Q3 | 1.02 Billion USD | 4.42% |
| 2007 Q2 | 889.41 Million USD | 2.06% |
| 2007 Q4 | 884.17 Million USD | -2.89% |
| 2007 Q3 | 910.51 Million USD | 2.37% |
| 2007 Q1 | 871.5 Million USD | -3.54% |
| 2007 FY | 884.17 Million USD | -2.13% |
| 2006 Q1 | 838.17 Million USD | 1.44% |
| 2006 Q3 | 885.89 Million USD | 2.73% |
| 2006 Q4 | 903.46 Million USD | 1.98% |
| 2006 FY | 903.46 Million USD | 9.34% |
| 2006 Q2 | 862.34 Million USD | 2.88% |
| 2005 Q2 | 657.43 Million USD | 12.2% |
| 2005 Q4 | 826.28 Million USD | 26.38% |
| 2005 FY | 826.28 Million USD | 80.94% |
| 2005 Q1 | 585.93 Million USD | 28.31% |
| 2005 Q3 | 653.79 Million USD | -0.55% |
| 2004 Q2 | 409.49 Million USD | 15.21% |
| 2004 Q3 | 392.69 Million USD | -4.1% |
| 2004 Q1 | 355.42 Million USD | 44.3% |
| 2004 FY | 456.66 Million USD | 85.4% |
| 2004 Q4 | 456.66 Million USD | 16.29% |
| 2003 Q3 | 204.44 Million USD | 76.49% |
| 2003 Q1 | 96.05 Million USD | 3504.39% |
| 2003 FY | 246.3 Million USD | 9142.36% |
| 2003 Q4 | 246.3 Million USD | 20.48% |
| 2003 Q2 | 115.83 Million USD | 20.59% |
| 2002 FY | 2.66 Million USD | 133.77% |
| 2002 Q4 | 2.66 Million USD | 133.57% |
| 2002 Q3 | 1.14 Million USD | 25.38% |
| 2002 Q2 | 910 Thousand USD | -43.62% |
| 2002 Q1 | 1.61 Million USD | 41.58% |
| 2001 Q4 | 1.14 Million USD | 1.42% |
| 2001 FY | 1.14 Million USD | -76.63% |
| 2001 Q2 | 2.17 Million USD | -4.3% |
| 2001 Q1 | 2.27 Million USD | -53.33% |
| 2001 Q3 | 1.12 Million USD | -48.42% |
| 2000 FY | 4.87 Million USD | -94.88% |
| 2000 Q1 | 57.25 Million USD | -39.92% |
| 2000 Q2 | 13.44 Million USD | -76.52% |
| 2000 Q3 | 17.42 Million USD | 29.59% |
| 2000 Q4 | 4.87 Million USD | -71.99% |
| 1999 Q4 | 95.3 Million USD | -18.41% |
| 1999 FY | 95.3 Million USD | -57.19% |
| 1999 Q1 | 186.6 Million USD | -16.17% |
| 1999 Q2 | 150 Million USD | -19.61% |
| 1999 Q3 | 116.8 Million USD | -22.13% |
| 1998 Q1 | 301.9 Million USD | -3.45% |
| 1998 FY | 222.6 Million USD | -28.81% |
| 1998 Q2 | 286.7 Million USD | -5.03% |
| 1998 Q3 | 259.3 Million USD | -9.56% |
| 1998 Q4 | 222.6 Million USD | -14.15% |
| 1997 Q2 | 182.1 Million USD | -7.56% |
| 1997 Q3 | 344.7 Million USD | 89.29% |
| 1997 Q4 | 312.7 Million USD | -9.28% |
| 1997 FY | 312.7 Million USD | 47.36% |
| 1997 Q1 | 197 Million USD | -7.16% |
| 1996 FY | 212.2 Million USD | 32.29% |
| 1996 Q1 | 144.4 Million USD | -9.98% |
| 1996 Q2 | 237.6 Million USD | 64.54% |
| 1996 Q4 | 212.2 Million USD | -6.77% |
| 1996 Q3 | 227.6 Million USD | -4.21% |
| 1995 Q1 | 273.7 Million USD | 0.0% |
| 1995 Q4 | 160.4 Million USD | -39.56% |
| 1995 Q2 | 273.5 Million USD | -0.07% |
| 1995 FY | 160.4 Million USD | 0.0% |
| 1995 Q3 | 265.4 Million USD | -2.96% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -6347.101% |
| Dynavax Technologies Corporation | 256.91 Million USD | -816.849% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -5572.245% |
| Perrigo Company plc | 4.07 Billion USD | 42.173% |
| Illumina, Inc. | 2.26 Billion USD | -4.134% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 93.254% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -235451.3% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 75.345% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 83.448% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -1255.668% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 12.852% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -8627.355% |
| Biogen Inc. | 7.33 Billion USD | 67.901% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -6081.8% |
| Evolus, Inc. | 126.54 Million USD | -1761.389% |
| Adicet Bio, Inc. | 17.7 Million USD | -13205.728% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -5356.745% |
| bluebird bio, Inc. | 330.32 Million USD | -613.087% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -335.442% |
| FibroGen, Inc. | 170.45 Million USD | -1281.897% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 13.875% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -11178.906% |
| Homology Medicines, Inc. | 44.05 Million USD | -5246.877% |
| Geron Corporation | 85.89 Million USD | -2642.189% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 1.772% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -429.259% |
| Myriad Genetics, Inc. | 145 Million USD | -1524.492% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -186845.476% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -1942.128% |
| Zoetis Inc. | 6.8 Billion USD | 65.375% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -53410.064% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -8.661% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -107.74% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -191.38% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -6384.908% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | -62.054% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -3970.212% |
| Verastem, Inc. | 41.55 Million USD | -5568.15% |
| Nektar Therapeutics | 230.4 Million USD | -922.354% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -1163.877% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -76526.968% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | -68.635% |
| OPKO Health, Inc. | 326.56 Million USD | -621.302% |
| Exelixis, Inc. | 189.94 Million USD | -1140.109% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -449.84% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -1559842.384% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -1601.85% |
| Imunon, Inc. | 1.13 Million USD | -206652.17% |
| Blueprint Medicines Corporation | 774.12 Million USD | -204.282% |
| Insmed Incorporated | 1.2 Billion USD | -95.642% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -57.113% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -4033.349% |
| TG Therapeutics, Inc. | 110.79 Million USD | -2026.01% |
| Incyte Corporation | 38.28 Million USD | -6052.253% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -168.435% |